Widdrol, a sesquiterpene isolated from Juniperus chinensis, inhibits angiogenesis by targeting vascular endothelial growth factor receptor 2 signaling

Oncology Reports

Volumn 34, Issue 3, 2015, Pages 1178-1184

  Jin, Soojung ^a   Yun, Hee Jung ^a   Jeong, Hyun Young ^a   Oh, You Na ^a   Park, Hyun Jin ^a   Yun, Seung Geun ^a   Kim, Byung Woo ^a   Kwon, Hyun Ju ^a  

^a Dong Eui University   (South Korea)

Author keywords

Anti angiogenesis; G1 arrest; Proliferation; Vascular endothelial growth factor receptor 2; Widdrol

Indexed keywords

CYCLIN DEPENDENT KINASE 2; DOXORUBICIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FOCAL ADHESION KINASE; PROTEIN KINASE B; PROTEIN P21; SESQUITERPENE DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2; WIDDROL; ANGIOGENESIS INHIBITOR; FUSED ALICYCLIC AROMATIC COMPOUND; PLANT EXTRACT; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2, HUMAN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; COLON ADENOCARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; DRUG ISOLATION; FEMALE; FLOW CYTOMETRY; HT 29 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; JUNIPERUS; JUNIPERUS CHINENSIS; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; METABOLISM; NEOVASCULARIZATION (PATHOLOGY);

ANGIOGENESIS INHIBITORS; ANIMALS; BENZOCYCLOHEPTENES; BLOTTING, WESTERN; FEMALE; FLOW CYTOMETRY; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; JUNIPERUS; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PLANT EXTRACTS; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84937198785     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.4075     Document Type: Article

References (32)

1. Folkman J: Tumor angiogenesis: Therapeutic implications. N Engl J Med 285: 1182-1186, 1971.
2. Kerbel RS: Tumor angiogenesis: Past, present and the near future. Carcinogenesis 21: 505-515, 2000.
3. Alon T, Hemo I, Itin A, Pe'er J, Stone J and Keshet E: Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1: 1024-1028, 1995.
4. Ferrara N: Vascular endothelial growth factor: Molecular and biological aspects. Curr Top Microbiol Immunol 237: 1-30, 1999.
5. Dvorak HF, Brown LF, Detmar M and Dvorak AM: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146: 1029-1039, 1995.
6. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R and Zeiher AM: Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399: 601-605, 1999.
7. Olsson AK, Dimberg A, Kreuger J and Claesson-Welsh L: VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 7: 359-371, 2006.
8. Ferrara N and Kerbel RS: Angiogenesis as a therapeutic target. Nature 438: 967-974, 2005.
9. Zheng X, Li A, Zhao L, Zhou T, Shen Q, Cui Q and Qin X: Key role of microRNA-15a in the KLF4 suppressions of proliferation and angiogenesis in endothelial and vascular smooth muscle cells. Biochem Biophys Res Commun 437: 625-631, 2013.
10. Roberts JM, Koff A, Polyak K, Firpo E, Collins S, Ohtsubo M and Massagué J: Cyclins, Cdks, and cyclin kinase inhibitors. Cold Spring Harb Symp Quant Biol 59: 31-38, 1994.
11. Sherr CJ and Roberts JM: CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev 13: 1501-1512, 1999.
12. Kwon HJ, Hong YK, Park C, Choi YH, Yun HJ, Lee EW and Kim BW: Widdrol induces cell cycle arrest, associated with MCM down-regulation, in human colon adenocarcinoma cells. Cancer Lett 290: 96-103, 2010.
13. Kwon HJ, Lee EW, Hong YK, Yun HJ and Kim BW: Widdrol from Juniperus chinensis induces apoptosis in human colon adenocarcinoma HT29 cells. Biotechnol Bioprocess Eng 15: 167-172, 2010.
14. Martínez-Poveda B, Muioz-Chápuli R, Rodríguez-Nieto S, Quintela J M, Fernández A, Medina MA and Quesada AR: IB05204, a dichloropyridodithienotriazine, inhibits angiogenesis in vitro and in vivo. Mol Cancer Ther 6: 2675-2685, 2007.
15. Argov M, Kashi R, Peer D and Margalit R: Treatment of resistant human colon cancer xenografts by a fluoxetine-doxorubicin combination enhances therapeutic responses comparable to an aggressive bevacizumab regimen. Cancer Lett 274: 118-125, 2009.
16. Folkman J: Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29 (Suppl 16): 15-18, 2002.
17. He D, Jin J, Zheng Y, Bruce IC, Tam S and Ma X: Anti-angiogenesis effect of trichosanthin and the underlying mechanism. Biochem Biophys Res Commun 430: 735-740, 2013.
18. Rössler J, Taylor M, Geoerger B, Farace F, Lagodny J , Peschka-Süss R, Niemeyer CM and Vassal G: Angiogenesis as a target in neuroblastoma. Eur J Cancer 44: 1645-1656, 2008.
19. Shizukuda Y, Tang S, Yokota R and Ware JA: Vascular endothelial growth factor-induced endothelial cell migration and proliferation depend on a nitric oxide-mediated decrease in protein kinase Cdelta activity. Circ Res 85: 247-256, 1999.
20. Taimeh Z, Loughran J, Birks EJ and Bolli R: Vascular endothelial growth factor in heart failure. Nat Rev Cardiol 10: 519-530, 2013.
21. Eskens FA and Verweij J: The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur J Cancer 42: 3127-3139, 2006.
22. Saraswati S, Kanaujia PK, Kumar S, Kumar R and Alhaider AA: Tylophorine, a phenanthraindolizidine alkaloid isolated from Tylophora indica exerts antiangiogenic and antitumor activity by targeting vascular endothelial growth factor receptor 2-mediated angiogenesis. Mol Cancer 12: 82, 2013.
23. Takahashi S: Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy. Biol Pharm Bull 34: 1785-1788, 2011.
24. Cheng JQ, Lindsley CW, Cheng GZ, Yang H and Nicosia SV: The Akt/PKB pathway: Molecular target for cancer drug discovery. Oncogene 24: 7482-7492, 2005.
25. Jiang BH and Liu LZ: AKT signaling in regulating angiogenesis. Curr Cancer Drug Targets 8: 19-26, 2008.
26. Yue GG, Chan BC, Kwok HF, Wong YL, Leung HW, Ji CJ, Fung KP, Leung PC, Tan NH and Lau CB: Anti-angiogenesis and immunomodulatory activities of an anti-tumor sesquiterpene bigelovin isolated from Inula helianthus-aquatica. Eur J Med Chem 59: 243-252, 2013.
27. Hong SW, Jung KH, Lee HS, Son MK, Yan HH, Kang NS, Lee J and Hong SS: SB365, Pulsatilla saponin D, targets c-Met and exerts antiangiogenic and antitumor activities. Carcinogenesis 34: 2156-2169, 2013.
28. Wang Y, Ma W and Zheng W: Deguelin, a novel anti-tumorigenic agent targeting apoptosis, cell cycle arrest and anti-angiogenesis for cancer chemoprevention. Mol Clin Oncol 1: 215-219, 2013.
29. Xiao D and Singh SV: Phenethyl isothiocyanate inhibits angiogenesis in vitro and ex vivo. Cancer Res 67: 2239-2246, 2007.
30. Liu JX, Luo MQ, Xia M, Wu Q, Long SM, Hu Y, Gao GC, Yao XL, He M, Su H, et al: Marine compound catunaregin inhibits angiogenesis through the modulation of phosphorylation of akt and eNOS in vivo and in vitro. Mar Drugs 12: 2790-2801, 2014.
31. Favot L, Keravis T and Lugnier C: Modulation of VEGF-induced endothelial cell cycle protein expression through cyclic AMP hydrolysis by PDE2 and PDE4. Thromb Haemost 92: 634-645, 2004.
32. Shi F, Wang YC, Zhao TZ, Zhang S, Du TY, Yang CB, Li YH and Sun XQ: Effects of simulated microgravity on human umbilical vein endothelial cell angiogenesis and role of the PI3K-Akt-eNOS signal pathway. PLoS One 7: e40365, 2012.